ProCE Banner Activity

Retrospective Analysis of Venetoclax + Hypomethylating Agents for Patients With Higher-Risk Myelodysplastic Syndromes

Slideset Download
Conference Coverage
Patients with higher-risk MDS who received venetoclax and a hypomethylating agent as first-line therapy had higher response rates than those receiving HMA alone.

Released: December 17, 2021

Expiration: December 16, 2022

Share

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AbbVie

AstraZeneca

Daiichi Sankyo, Inc.

GlaxoSmithKline

Incyte Corporation

Jazz Pharmaceuticals, Inc.

Merck Sharp & Dohme Corp.

Novartis Pharmaceuticals Corporation